1. Long-Term Treatment With Entecavir Induces Reversal of Advanced Fibrosis or Cirrhosis in Patients With Chronic Hepatitis B 
Eugene R. Schiff, Samuel S. Lee, You–Chen Chao, Seung Kew Yoon, Fernando Bessone, Shun–Sheng Wu, Wieslaw Kryczka, Yoav Lurie, Adrian Gadano, George Kitis, Suzanne Beebe, Dong Xu, Hong Tang, Uchenna Iloeje 
Clinical Gastroenterology and Hepatology 
Volume 9, Issue 3, Pages e1 (March 2011)
DOI: /j.cgh
Copyright © 2011 AGA Institute Terms and Conditions

2. Figure 1
(A) Distribution of Knodell necroinflammatory scores at 3 biopsy time points taken at baseline, after 48 weeks (year 1) of entecavir therapy, and at the time of long-term biopsy (median, 6 y) among a subset of patients from the long-term histology cohort with an Ishak fibrosis score of 4 or greater at baseline (n = 10). (B) Distribution of Ishak fibrosis scores at 3 biopsy time points taken at baseline, after 48 weeks (year 1) of entecavir therapy, and at the time of long-term biopsy (median, 6 y) among a subset of patients from the long-term histology cohort with an Ishak fibrosis score of 4 or greater at baseline (n = 10).
Clinical Gastroenterology and Hepatology 2011 9, e1DOI: ( /j.cgh )
Copyright © 2011 AGA Institute Terms and Conditions